Literature DB >> 19944582

Harm reduction policies for tobacco users.

Coral Gartner1, Wayne Hall.   

Abstract

Tobacco harm reduction is a controversial policy due to the experience with filtered and 'light' cigarettes and concerns that the tobacco industry will use reduced harm products to undermine tobacco control strategies. The most promising harm reduction products are high dose pharmaceutical nicotine preparations and low nitrosamine smokeless tobacco, such as Swedish snus. However, despite widespread availability, existing pharmaceutical nicotine preparations have not been taken up by smokers as an alternative to smoking. In Sweden, increased snus use was associated with decreased cigarette smoking and mortality from tobacco-related disease. We suggest a graduated series of policies to explore of the public health costs and benefits of encouraging smokers to switch to these less harmful nicotine products. Copyright (c) 2009 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19944582     DOI: 10.1016/j.drugpo.2009.10.008

Source DB:  PubMed          Journal:  Int J Drug Policy        ISSN: 0955-3959


  7 in total

1.  Oral tobacco products: preference and effects among smokers.

Authors:  Dorothy K Hatsukami; Joni Jensen; Amanda Anderson; Berry Broadbent; Sharon Allen; Yan Zhang; Herb Severson
Journal:  Drug Alcohol Depend       Date:  2011-04-23       Impact factor: 4.492

Review 2.  The reinforcement threshold for nicotine as a target for tobacco control.

Authors:  Mehmet Sofuoglu; Mark G LeSage
Journal:  Drug Alcohol Depend       Date:  2012-05-21       Impact factor: 4.492

3.  Snus use and rejection in the USA.

Authors:  Lois Biener; Anthony M Roman; Scott A Mc Inerney; Dragana Bolcic-Jankovic; Dororthy K Hatsukami; Alexandra Loukas; Richard J O'Connor; Laura Romito
Journal:  Tob Control       Date:  2014-02-25       Impact factor: 7.552

4.  Trends in point-of-sale tobacco marketing around college campuses: Opportunities for enhanced tobacco control efforts.

Authors:  Kimberly G Wagoner; Erin L Sutfin; Eunyoung Y Song; Jessica L King; Kathleen L Egan; Beth Reboussin; Beata Debinski; John Spangler; Mark Wolfson
Journal:  J Am Coll Health       Date:  2018-01-09

5.  US smokers' reactions to a brief trial of oral nicotine products.

Authors:  Richard J O'Connor; Kaila J Norton; Maansi Bansal-Travers; Martin C Mahoney; K Michael Cummings; Ron Borland
Journal:  Harm Reduct J       Date:  2011-01-10

Review 6.  The health impact of smokeless tobacco products: a systematic review.

Authors:  C Hajat; E Stein; L Ramstrom; S Shantikumar; R Polosa
Journal:  Harm Reduct J       Date:  2021-12-04

7.  Transcriptome sequencing reveals e-cigarette vapor and mainstream-smoke from tobacco cigarettes activate different gene expression profiles in human bronchial epithelial cells.

Authors:  Yifei Shen; Michael J Wolkowicz; Tatyana Kotova; Lonjiang Fan; Michael P Timko
Journal:  Sci Rep       Date:  2016-04-04       Impact factor: 4.379

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.